[HTML][HTML] Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
L Zhao, J Hu, D Hu, H Wang, C Huang, R Luo… - Biomedicine & …, 2022 - Elsevier
Immunotherapy is now a mainstay in cancer treatments. Programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have …
1)/programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitor (ICI) therapies have …
Ability of blood cell parameters to predict clinical outcomes of nivolumab monotherapy in advanced esophageal squamous cell carcinoma
Y Hamai, M Emi, Y Ibuki, T Kurokawa… - OncoTargets and …, 2023 - Taylor & Francis
Purpose Various blood cell parameters have been identified as predictive markers of tumor
responses and the survival of patients with cancer treated with immune checkpoint …
responses and the survival of patients with cancer treated with immune checkpoint …
Clinical benefit of pembrolizumab in advanced urothelial cancer patients in real-life setting: an efficacy and safety monocentric study
E Dang, A Vallée, C Lepage-Seydoux, K Sejean… - Current …, 2022 - mdpi.com
Background: Pembrolizumab is approved for patients with metastatic urothelial carcinoma
(UC) who progressed under platinum therapy. The aim of this study was to assess the …
(UC) who progressed under platinum therapy. The aim of this study was to assess the …
Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model
A Pezeshki, JC Cheville, AB Florio… - Frontiers in …, 2024 - frontiersin.org
Background Only 20 percent of renal and bladder cancer patients will show a significant
response to immune checkpoint inhibitor (ICI) therapy, and no test currently available …
response to immune checkpoint inhibitor (ICI) therapy, and no test currently available …
[HTML][HTML] Bilateral pleural effusion associated with atezolizumab in a patient with Lynch syndrome-related urothelial carcinoma: a case report
HY Yhim, SY Jeon, CH Lee… - Annals of Palliative …, 2022 - apm.amegroups.org
Lynch syndrome (LS) is an inherited syndrome associated with an increased risk of cancer
caused by abnormalities in DNA mismatch repair (MMR) genes. Immune checkpoint …
caused by abnormalities in DNA mismatch repair (MMR) genes. Immune checkpoint …
[PDF][PDF] Is there an Association between Lymph Node Size and Hyperprogression in Immunotherapy-Treated Patients?
MS Alkader, RZ Altaha, EH Jabali, OA Attieh… - Romanian Journal of …, 2023 - sciendo.com
Background: Hyperprogressive disease (HPD) can be described as an accelerated increase
in the growth rate of tumors combined with rapid clinical deterioration observed in a subset …
in the growth rate of tumors combined with rapid clinical deterioration observed in a subset …
Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report
S Dong, K Liu, R Liu, J Zhuang - Experimental and …, 2022 - spandidos-publications.com
Immunotherapy through blocking programmed cell death 1, programmed death‑ligand 1 and
cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention …
cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention …
[HTML][HTML] PD-1/PD-L1 抑制剂在食管癌治疗中的进展
张艳利， 魏素菊 - Advances in Clinical Medicine, 2022 - hanspub.org
食管癌不仅是目前世界上第八大常见的恶性癌症, 也是导致癌症及其相关患者死亡的第六大常见
死亡原因. 通过免疫检查点抑制剂治疗提高了晚期黑色素瘤, 非小细胞肺癌等恶性肿瘤患者的 …
死亡原因. 通过免疫检查点抑制剂治疗提高了晚期黑色素瘤, 非小细胞肺癌等恶性肿瘤患者的 …
[HTML][HTML] Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report
M Alkader, R Altaha, L Alkhatib, EH Jabali… - Cureus, 2022 - ncbi.nlm.nih.gov
Owing to their survival benefits, immune checkpoint inhibitors (ICIs) have emerged as the
mainstay treatment for several types of malignant tumors including renal cell carcinoma …
mainstay treatment for several types of malignant tumors including renal cell carcinoma …